Loading...
The search goes on for effective medical treatment of nonalcoholic steatohepatitis (NASH). The following are phase IIb trial results for cenicriviroc, an oral, dual antagonist of C-C motif chemokine receptor types 2 and 5 that seems to have anti-inflammatory and antifibrotic properties.
Investigators randomized 289 patients with NASH, a nonalcoholic fatty liver disease activity score (NAS) ≥4, and fibrosis (stages 1 to 3) to receive cenicriviroc 150 mg or placebo once daily. The primary endpoint was an improvement in NAS of ≥2 points and no worsening of fibrosis at the end of 1 year of treatment.
Improvement in NAS was similar between groups (16% in the cenicriviroc group and 19% in the placebo group). However, a significantly greater proport…